James Woodruff Emlen
Direttore Tecnico/Scientifico/R&S presso MenoGenix, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Debra M. Duke | F | - |
MenoGenix, Inc.
MenoGenix, Inc. BiotechnologyHealth Technology MenoGenix, Inc. operates as a biotechnology company. It focuses on development of drugs for menopause and the menopause diseases. The company was founded by Debra M. Duke and Jonathan Kaufman in 2010 and is headquartered in Aurora, CO. | 14 anni |
Richard Duke | M | - |
MenoGenix, Inc.
MenoGenix, Inc. BiotechnologyHealth Technology MenoGenix, Inc. operates as a biotechnology company. It focuses on development of drugs for menopause and the menopause diseases. The company was founded by Debra M. Duke and Jonathan Kaufman in 2010 and is headquartered in Aurora, CO. | - |
T. Richard Fort | M | - |
MenoGenix, Inc.
MenoGenix, Inc. BiotechnologyHealth Technology MenoGenix, Inc. operates as a biotechnology company. It focuses on development of drugs for menopause and the menopause diseases. The company was founded by Debra M. Duke and Jonathan Kaufman in 2010 and is headquartered in Aurora, CO. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
V. Michael Holers | M | - |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | 8 anni |
Abbie Celniker | M | 65 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | 3 anni |
Timothy C. Mills | M | 68 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | - |
Bill Lundberg | M | 60 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | 2 anni |
Nicholas G. Galakatos | M | 66 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | - |
Jill Porter | M | - |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | - |
Edward Hurwitz | M | 60 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | - |
John Maraganore | M | 60 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | 2 anni |
Martin Freed | M | 63 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | 1 anni |
Jeffrey Walsh | M | 58 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | 3 anni |
Christopher Horvath | M | - |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | - |
Karen L. Tubridy | M | 61 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | 1 anni |
Jason Ryan | M | 49 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | 2 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 16 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- James Woodruff Emlen
- Contatti personali